Overview

This trial is active, not recruiting.

Condition lung cancer
Treatments carboplatin, erlotinib hydrochloride, paclitaxel
Phase phase 2
Target EGFR
Sponsor Southwest Oncology Group
Collaborator National Cancer Institute (NCI)
Start date December 2008
End date February 2015
Trial size 98 participants
Trial identifier NCT00661193, CDR0000593575, S0709, U10CA032102

Summary

RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving erlotinib together with carboplatin and paclitaxel may kill more tumor cells.

PURPOSE: This randomized phase II trial is studying how well erlotinib works when given alone or together with carboplatin and paclitaxel in treating patients with stage IIIB or stage IV non-small cell lung cancer.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
Arm
(Active Comparator)
Patients receive oral erlotinib hydrochloride once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
erlotinib hydrochloride
given orally
(Active Comparator)
Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and oral erlotinib hydrochloride once daily on days 2-16. Treatment repeats every 21 days for 4 courses. Beginning in course 5 and for all subsequent courses, patients receive oral erlotinib hydrochloride alone on days 1-21. Courses with erlotinib hydrochloride repeat every 21 days in the absence of disease progression or unacceptable toxicity.
carboplatin
given IV
erlotinib hydrochloride
given orally
paclitaxel
given IV

Primary Outcomes

Measure
Selection of one of two treatment regimens (erlotinib hydrochloride with or without carboplatin and paclitaxel) for further study in a phase III trial, based on median progression-free survival for ≥ 3 months
time frame: From date of registration to 3 years or death, whichever comes first

Secondary Outcomes

Measure
Response rate (confirmed and unconfirmed, complete and partial response) in a subset of patients with measurable disease
time frame: From date of registration to 3 years or death, whichever comes first

Eligibility Criteria

Male or female participants at least 18 years old.

DISEASE CHARACTERISTICS: - Histologically or cytologically confirmed non-small cell lung cancer (NSCLC), including any of the following subtypes: - Adenocarcinoma - Large cell carcinoma - Squamous cell carcinoma - Unspecified - Newly diagnosed primary disease OR recurrent disease after prior surgery and/or radiotherapy, meeting 1 of the following staging criteria: - Selected stage IIIB disease (T4 [secondary to malignant pleural effusion only], any N, M0) - Stage IV disease (any T, any N, M1 [distant metastases present]) - Measurable or nonmeasurable disease by CT scan, MRI, x-ray, physical exam, or nuclear scan - The CT scan from a combined PET/CT scan may only be used to document nonmeasurable disease - Pleural effusions, ascites, and laboratory parameters are not acceptable as the only evidence of disease - Shows evidence of EGFR tyrosine kinase inhibitor therapy benefit (i.e., "proteomics positive") prior to study registration - No untreated brain metastases - Patients with treated brain metastases are allowed provided metastases have remained controlled for at least two weeks following treatment, AND patient has no residual neurological dysfunction off corticosteroids - Patients with neurologic abnormalities on physical examination or symptoms must have a negative pretreatment CT or MRI scan of the brain 28 days prior to registration PATIENT CHARACTERISTICS: - Zubrod performance status 2 - ANC ≥ 1,500/mm³ - Platelet count ≥ 1,000/mm³ - Serum bilirubin normal - SGOT or SGPT normal - Serum creatinine ≤ 2 times upper limit of normal OR creatinine clearance ≥ 50 mL/min - Willing to provide prior smoking history as requested on the prestudy form - No gastrointestinal (GI) tract disease resulting in an inability to take enteral medication - No malabsorption syndrome or requirement for IV alimentation - No uncontrolled inflammatory GI disease (e.g., Crohn's disease or ulcerative colitis) - No significant history of cardiac disease, including any of the following: - Uncontrolled high blood pressure - Unstable angina - Congestive heart failure - Myocardial infarction within the past 6 months - Cardiac ventricular arrhythmia requiring medication - No other prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for 5 years - Not pregnant or nursing - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: - See Disease Characteristics - At least 3 weeks since prior radiotherapy or surgery (thoracic or other major surgery) and recovered - At least 1 year since prior adjuvant chemotherapy - No prior systemic hormonal therapy, chemotherapy, or biological therapy for advanced NSCLC - No prior EGFR inhibitors - No prior surgical procedures affecting absorption - No concurrent major surgery

Additional Information

Official title A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Description OBJECTIVES: Primary - To select a regimen (erlotinib hydrochloride with or without carboplatin and paclitaxel) for further testing against standard treatment, based on median progression-free survival for ≥ 3 months, in patients with stage IIIB or IV non-small cell lung cancer with a Zubrod performance status of 2. Secondary - To assess the feasibility of selecting patients for a trial based on central EGFR testing of serum in a cooperative group setting. - To evaluate the objective tumor response rates (confirmed and unconfirmed, complete and partial response), in a subset of patients with measurable disease. OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 treatment arms. - Arm I: Patients receive oral erlotinib hydrochloride once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. - Arm II: Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and oral erlotinib hydrochloride once daily on days 2-16. Treatment repeats every 21 days for 4 courses. Beginning in course 5 and for all subsequent courses, patients receive oral erlotinib hydrochloride alone on days 1-21. Courses with erlotinib hydrochloride repeat every 21 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed every 3 months for 1 year and then every 6 months for 2 years.
Trial information was received from ClinicalTrials.gov and was last updated in February 2015.
Information provided to ClinicalTrials.gov by Southwest Oncology Group.